Dr. Malin Hultcrantz

Dr. Malin Hultcrantz, MD, PhD, is a board-certified hematologist specializing in multiple myeloma and related plasma cell disorders, including the precursor conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. She practices at Memorial Sloan Kettering Cancer Center, where she works alongside colleagues to optimize treatment strategies for patients with multiple myeloma. Her clinical practice encompasses a broad range of modern therapeutic options, including clinical trials and novel immunotherapies, with a strong emphasis on improving quality of life for patients undergoing treatment.

Dr. Hultcrantz has a particular research focus on understanding the mechanisms and markers of progression from precursor plasma cell disorders to active multiple myeloma. Her work includes the development of targeted genomic tests for disease characterization and the measurement of minimal residual disease. Through a deeper understanding of disease biology, her research aims to improve risk stratification and enable more personalized treatment approaches, including early intervention for patients identified as having high-risk precursor disease.

Her dual background in clinical medicine and research, reflected in both her MD and PhD credentials, positions her at the intersection of translational science and patient care. By linking laboratory discoveries to clinical practice, Dr. Hultcrantz continues to advance the field of plasma cell disorders, working toward earlier detection, more precise treatment planning, and better outcomes for patients across the full spectrum of myeloma-related conditions.